These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

879 related articles for article (PubMed ID: 34486094)

  • 21. The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry.
    Sato T; Aizawa Y; Fuse K; Fujita S; Ikeda Y; Kitazawa H; Takahashi M; Okabe M
    J Stroke Cerebrovasc Dis; 2018 Nov; 27(11):3280-3288. PubMed ID: 30121155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States.
    Sandhu A; Kaltenbach LA; Chiswell K; Shimoga V; Ashur C; Pribish A; Fonarow GC; Piccini JP; Ho PM; Varosy PD; Hess PL
    Circ Cardiovasc Qual Outcomes; 2023 Dec; 16(12):e010062. PubMed ID: 37929603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns and outcomes of switching direct oral anticoagulants in non-valvular atrial fibrillation: A real-world experience from Spain.
    Rodilla E; Orts-Martínez MI; Sanz-Caballer MA; Gimeno-Brosel MT; Arilla-Morel MJ; Navarro-Gonzalo I; Castillo-Valero I; Salvador-Mercader I; Carral-Tatay A
    Rev Clin Esp (Barc); 2023; 223(6):340-349. PubMed ID: 37105383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants.
    Abdrakhmanov A; Shaimerdinova A; Suleimen Z; Abildinova S; Albayev R; Tuyakova G; Rib E; Beysenbayeva A; Kabduyeva G; Bekbossynova M
    Ther Adv Cardiovasc Dis; 2024; 18():17539447241249886. PubMed ID: 38801157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): an interrupted time series analysis (January 2019-February 2021).
    Alkhameys S; Barrett R
    Curr Med Res Opin; 2022 Jul; 38(7):1081-1092. PubMed ID: 35582854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
    Collings SL; Vannier-Moreau V; Johnson ME; Stynes G; Lefèvre C; Maguire A; Asmar J; Bizouard G; Duhot D; Mouquet F; Fauchier L
    Arch Cardiovasc Dis; 2018 May; 111(5):370-379. PubMed ID: 29398546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis.
    Deitelzweig S; Bergrath E; di Fusco M; Kang A; Savone M; Cappelleri JC; Russ C; Betts M; Cichewicz A; Schaible K; Tarpey J; Fahrbach K
    Future Cardiol; 2022 May; 18(5):393-405. PubMed ID: 35360925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inappropriate direct oral anticoagulant prescriptions in patients with non-valvular atrial fibrillation: cross-sectional analysis of the French CACAO cohort study in primary care.
    Ferrat E; Fabre J; Galletout P; Boutin E; Le Breton J; Renard V; Frappé P; Bastuji-Garin S
    Br J Gen Pract; 2021; 71(703):e134-e139. PubMed ID: 33495204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase Registry.
    Navarro-Almenzar B; Cerezo-Manchado JJ; Caro-Martinez C; García-Candel F; Flores Blanco PJ; Ruiz GE; Andreu Cayuelas JM; Montoya FA; Cascales A; Lova Navarro A; García Alberola A; Andrés Pascual Figal D; Bailen Lorenzo JL; Manzano-Fernández S
    Curr Med Res Opin; 2019 Dec; 35(12):2035-2041. PubMed ID: 31335222
    [No Abstract]   [Full Text] [Related]  

  • 32. Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.
    Blomström Lundqvist C; Själander S; Garcia Rodriguez LA; Åkerborg Ö; Jin G; Caleyachetty A; Huelsebeck M; Bowrin K; Schaefer B; Mahdessian H; Hofmeister L; Levin LÅ
    J Med Econ; 2022; 25(1):1085-1091. PubMed ID: 35997241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
    Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M
    Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints.
    Zielinski GD; Teichert M; Klok FA; Rosendaal FR; Huisman MV; Cannegieter SC; Lijfering WM
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1371-1378. PubMed ID: 30443944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.
    Lau WCY; Torre CO; Man KKC; Stewart HM; Seager S; Van Zandt M; Reich C; Li J; Brewster J; Lip GYH; Hingorani AD; Wei L; Wong ICK
    Ann Intern Med; 2022 Nov; 175(11):1515-1524. PubMed ID: 36315950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation.
    Sugrue A; Sanborn D; Amin M; Farwati M; Sridhar H; Ahmed A; Mehta R; Siontis KC; Mulpuru SK; Deshmukh AJ; Gersh BJ; Asirvatham SJ; Madhavan M
    Am J Cardiol; 2021 Apr; 144():52-59. PubMed ID: 33385355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral Anticoagulation in Patients in the Emergency Department: High Rates of Off-Label Doses, No Difference in Bleeding Rates.
    Eschler CM; Woitok BK; Funk GC; Walter P; Maier V; Exadaktylos AK; Lindner G
    Am J Med; 2020 May; 133(5):599-604. PubMed ID: 31668901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
    Nosáľ V; Petrovičová A; Škorňová I; Bolek T; Dluhá J; Stančiaková L; Sivák Š; Babálová L; Hajaš G; Staško J; Kubisz P; Kurča E; Samoš M; Mokáň M
    Eur J Clin Pharmacol; 2022 Apr; 78(4):557-564. PubMed ID: 35066599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.
    Jackevicius CA; Lu L; Ghaznavi Z; Warner AL
    Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007230. PubMed ID: 33541109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.